<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01932541</url>
  </required_header>
  <id_info>
    <org_study_id>2013-P-001524</org_study_id>
    <nct_id>NCT01932541</nct_id>
  </id_info>
  <brief_title>Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old</brief_title>
  <official_title>Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old With Bipolar I, Bipolar II and Bipolar Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an 8-week open-label trial testing Lurasidone (Latuda®) as a treatment for&#xD;
      mania in children and adolescents with Bipolar I, Bipolar II, and Bipolar Spectrum disorders.&#xD;
      We hypothesize that Lurasidone will be safe, tolerable, and effective in improving the core&#xD;
      symptoms of bipolar disorders in children and adolescents ages 6-17.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    On hold due to competing departmental studies&#xD;
  </why_stopped>
  <start_date>January 2017</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Young Mania Rating Scale</measure>
    <time_frame>Change from baseline at 12 weeks</time_frame>
    <description>This is a widely used instrument that assesses symptoms of mania in clinical trials of adult and pediatric subjects.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Mania</condition>
  <condition>Bipolar I</condition>
  <condition>Bipolar II</condition>
  <condition>Bipolar Spectrum Disorder</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Latuda (Lurasidone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latuda (Lurasidone)</intervention_name>
    <description>Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.</description>
    <arm_group_label>Latuda (Lurasidone)</arm_group_label>
    <other_name>Lurasidone</other_name>
    <other_name>Latuda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects 6-17 years of age&#xD;
&#xD;
          2. Subjects must weigh at least 20 kg&#xD;
&#xD;
          3. Subjects with the diagnosis of bipolar I, bipolar II, or bipolar spectrum disorder and&#xD;
             currently displaying manic, hypomanic, or mixed symptoms (with or without psychotic&#xD;
             features), by DSM-IV (Diagnostic and Statistical Manual IV), as manifested in clinical&#xD;
             evaluation and/or the Mania module of the structured interview, completed by the study&#xD;
             clinician. Bipolar Spectrum Disorder (or sub-threshold bipolar disorder) is&#xD;
             operationalized as having severe mood disturbance, which meets DSM-IV Criteria A for&#xD;
             bipolar disorder but displays fewer elements in Criteria B (only require 2 items for&#xD;
             elation category and 3 for irritability)&#xD;
&#xD;
          4. Subjects must score ≥ 20 on the YMRS (Young Mania Rating Scale)&#xD;
&#xD;
          5. Subjects and their legal representative must have a level of understanding sufficient&#xD;
             to communicate intelligently with the investigator and study coordinator, and to&#xD;
             cooperate with all tests and examinations required by the protocol.&#xD;
&#xD;
          6. Subjects and their legal representative must be considered reliable reporters.&#xD;
&#xD;
          7. Each subject and his/her authorized legal representative must understand the nature of&#xD;
             the study. The subject's authorized legal representative must sign an informed consent&#xD;
             document and the subject must sign an informed assent document (if ≥ 7 years old).&#xD;
&#xD;
          8. Subject must be able to participate in mandatory blood draws.&#xD;
&#xD;
          9. Subject must be able to swallow pills.&#xD;
&#xD;
         10. Subjects with co-morbid PDD (Pervasive Developmental Disorder) and depressive&#xD;
             disorders will be allowed to participate in the study provided they do not meet any of&#xD;
             the exclusionary criteria.&#xD;
&#xD;
         11. For concomitant therapy used to treat ADHD (Attention Deficit Hyperactivity Disorder),&#xD;
             subjects must have been on a stable dose of the medication for 1 month prior to study&#xD;
             enrollment, and the dose of the ADHD therapy cannot change throughout the duration of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Investigator and his/her immediate family; defined as the investigator's spouse,&#xD;
             parent, child, grandparent, or grandchild.&#xD;
&#xD;
          2. Serious, unstable illness including hepatic, renal, gastroenterological, respiratory,&#xD;
             cardiovascular (including ischemic heart disease), endocrinologic, neurologic,&#xD;
             immunologic, or hematologic disease.&#xD;
&#xD;
          3. Uncorrected hypothyroidism or hyperthyroidism.&#xD;
&#xD;
          4. Non-febrile seizures without a clear and resolved etiology.&#xD;
&#xD;
          5. DSM-IV substance (except nicotine or caffeine) dependence within past 6 months.&#xD;
&#xD;
          6. Judged clinically to be at serious suicidal risk or have a C-SSRS (Columbia Suicide&#xD;
             Severity Rating Scale) score ≥ 4.&#xD;
&#xD;
          7. Any other concomitant medication with primary central nervous system activity other&#xD;
             than specified in the Concomitant Medication portion of the Protocol.&#xD;
&#xD;
          8. Current diagnosis of schizophrenia.&#xD;
&#xD;
          9. Mental retardation (IQ &lt; 75)&#xD;
&#xD;
         10. Pregnant or nursing females&#xD;
&#xD;
         11. Known hypersensitivity to Latuda®&#xD;
&#xD;
         12. A non-responder or history of intolerance to Latuda®, after treatment at adequate&#xD;
             doses as determined by the clinician.&#xD;
&#xD;
         13. Severe allergies or multiple adverse drug reactions.&#xD;
&#xD;
         14. Subjects with a hematological disorder.&#xD;
&#xD;
         15. Subjects with diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Wozniak, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital Clinical and Research Program in Pediatric Psychopharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>August 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2013</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet Wozniak, MD</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry, Harvard Medical School; Director, Pediatric Bipolar Clinical and Research Program in Pediatric Psychopharmacology, Massachusetts General Hospital.</investigator_title>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Mania</keyword>
  <keyword>Bipolar I</keyword>
  <keyword>Bipolar II</keyword>
  <keyword>Bipolar Spectrum Disorder</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mania</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

